Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioAlliance SA Out-licenses Loramyc in China to NovaMed Pharma

publication date: Jun 24, 2008

BioAlliance Pharma SA has licensed the China commercialization rights for Loramyc™ to NovaMed Pharmaceuticals. The deal could be worth up to $4.5 million to NovaMed in upfront and milestone payments. NovaMed will seek to win SFDA approval for the product and then market it in China. Loramyc (miconazole Lauriad®) is a muco-adhesive antifungal therapy that is already approved in some European countries for cancer patients with opportunistic infections.  More details... 

Stock Symbol: (Euronext Paris: BIO)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here